Intellia Therapeutics
NTLA
76 hedge funds and large institutions have $236M invested in Intellia Therapeutics in 2017 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 11 closing their positions.
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
9% more funds holding
Funds holding: 70 → 76 (+6)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
2% less capital invested
Capital invested by funds: $241M → $236M (-$5.18M)
4.6% less ownership
Funds ownership: 51.07% → 46.47% (-4.6%)
20% less call options, than puts
Call options by funds: $478K | Put options by funds: $599K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.7M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$4.44M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.29M |
| 4 |
PC
Paulson & Co
New York
|
+$1.05M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$715K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.3M |
| 2 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$9.39M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$7.43M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.83M |
| 5 |
Millennium Management
New York
|
-$1.78M |
NTLA Hedge Fund Activity: Q1 2017 in Review
76 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2017, worth a combined $236M — down 2.2% from $241M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new NTLA positions and 11 closed out — a net gain of 12 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $12.7M. The largest seller was Fidelity Investments, cutting an estimated $10.3M.
- 76 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2017, up from 70 in Q4 2016.
- Funds reported $236M of Intellia Therapeutics stock for Q1 2017, down 2.2% quarter-over-quarter.
- 23 funds opened new Intellia Therapeutics positions in Q1 2017 and 11 closed out, a net change of +12 holders.
- The largest Intellia Therapeutics buyer in Q1 2017 was BlackRock, an estimated $12.7M added.
- The largest Intellia Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $10.3M sold.
Based on aggregated 13F filings for Q1 2017.